Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Glomerulonephritis
How does your approach to the differential diagnosis of membranous nephropathy change when PLA2R positivity is detected alongside a chronic viral infection such as HIV, HBV, or HCV?
Related Questions
Which clinical characteristics would prompt you to consider an oral factor B inhibitor such as iptacopan in the treatment of IgA nephropathy?
How would you approach a patient with class III and V lupus nephritis, already on HCQ, MMF, voclosporin and losartan, but has continued proteinuria not yet attaining complete renal response?
What factors do you consider when advising a patient with lupus nephritis on the safety of becoming pregnant?
How would you approach the treatment of crescentic fibrillary glomerulonephritis?
Do you use delayed-release budesonide over prednisone or methylprednisolone for the treatment of IgA nephropathy, considering the available safety and efficacy data?
What is your approach to treating IgA nephropathy in patients who also have IgA vasculitis?
Under what circumstances would you consider obinutuzumab instead of rituximab when treating primary membranous nephropathy?
How do you manage oral prednisone when initiating nefecon in a patient with IgA nephropathy?
How do you counsel patients who are found to have a carrier mutation in a single high-risk APOL1 allele?
Do you recommend initiating immunosuppression and plasmapheresis in patients with dialysis dependent AKI in the setting of anti-GBM disease who do not have pulmonary involvement?
